The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts

Analysts' ratings for GeneDx Hldgs (NASDAQ:WGS) over the last quarter vary from bullish to bearish, as provided by 6 analysts.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	0	3	0	0
Last 30D	0	0	1	0	0
1M Ago	0	0	0	0	0
2M Ago	0	0	1	0	0
3M Ago	3	0	1	0	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $43.5, a high estimate of $54.00, and a low estimate of $32.00. This current average has increased by 18.21% from the previous average price target of $36.80.

Decoding Analyst Ratings: A Detailed Look

The standing of GeneDx Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Matthew Sykes	Goldman Sachs	Raises	Neutral	$54.00	$32.00
Brandon Couillard	Wells Fargo	Announces	Equal-Weight	$34.00	-
Dan Brennan	TD Cowen	Raises	Buy	$50.00	$46.00
Mark Massaro	BTIG	Raises	Buy	$45.00	$35.00
Bill Bonello	Craig-Hallum	Raises	Buy	$46.00	$43.00
Matthew Sykes	Goldman Sachs	Raises	Neutral	$32.00	$28.00

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GeneDx Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GeneDx Hldgs compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GeneDx Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on GeneDx Hldgs analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into GeneDx Hldgs's Background

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

Financial Insights: GeneDx Hldgs

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: GeneDx Hldgs displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 44.77%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: GeneDx Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -41.37%, the company may face hurdles in effective cost management.

Return on Equity (ROE): GeneDx Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.54%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): GeneDx Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.45%, the company may face hurdles in achieving optimal financial returns.

Debt Management: With a below-average debt-to-equity ratio of 0.6, GeneDx Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.